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Abstract
The CATERPILLER (CLR, also NOD and NLR) proteins share structural similarities with the
nucleotide binding domain (NBD)-leucine-rich repeat (LRR) superfamily of plant disease-resistance
(R) proteins and are emerging as important immune regulators in animals. CLR proteins contain
NBD-LRR motifs and are linked to a limited number of distinct N-terminal domains including
transactivation, CARD (caspase activation and recruitment), and pyrin domains (PyD). The CLR
gene, Monarch-1/Pypaf7, is expressed by resting primary myeloid/monocytic cells, and its
expression in these cells is reduced by Toll-like receptor (TLR) agonists tumor necrosis factor (TNF)
α and Mycobacterium tuberculosis. Monarch-1 reduces NFκB activation by TLR-signaling
molecules MyD88, IRAK-1 (type I interleukin-1 receptor-associated protein kinase), and TRAF6
(TNF receptor (TNFR)-associated factor) as well as TNFR signaling molecules TRAF2 and RIP1
but not the downstream NFκB subunit p65. This indicates that Monarch-1 is a negative regulator of
both TLR and TNFR pathways. Reducing Monarch-1 expression with small interference RNA in
myeloid/ monocytic cells caused a dramatic increase in NFκB activation and cytokine expression in
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response to TLR2/TLR4 agonists, TNFα, or M. tuberculosis infection, suggesting that Monarch-1
is a negative regulator of inflammation. Because Monarch-1 is the first CLR protein that interferes
with both TLR2 and TLR4 activation, the mechanism of this interference is significant. We find that
Monarch-1 associates with IRAK-1 but not MyD88, resulting in the blockage of IRAK-1
hyperphosphorylation. Mutants containing the NBD-LRR or PyD-NBD also blocked IRAK-1
activation. This is the first example of a CLR protein that antagonizes inflammatory responses
initiated by TLR agonists via interference with IRAK-1 activation.
Plants have several classes of disease-resistant genes (R genes) that enable host defense to a
wide variety of pathogens. A major class of R genes encodes proteins that contain an N-terminal
Toll-like receptor (TLR)2/IL-1 receptor or leucine zipper domain followed by a nucleotide
binding domain (NBD) and a C-terminal leucine-rich repeat (LRR). In mammals the class II
transactivator and NOD1/NOD2 proteins were initially identified as proteins with a similar
arrangement of NBD and LRR domains. More recently, our laboratory identified a 20+ member
family of genes in humans that we called the CATERPILLER (CARD, transcription enhancer,
r(purine) binding, pyrin, lots of leucine repeats) gene family (1). Subsequently, others described
a similar family and designated it as NOD (2, 3), whereas others described a subgroup with a
pyrin domain designated as the NALP, PAAD/PAN, and PYPAF families (3–6). By definition,
all CLR proteins contain NBD-LRR motifs and are linked to a limited number of distinct N-
terminal domains including transactivation, CARD (caspase activation and recruitment), and
pyrin domains (PyD) (1). A great majority of CLR proteins contain a PyD, originally defined
as a domain within the PYRIN protein that has been linked to familial Mediterranean fever
(MEFV) (7). The PyD has recently been characterized as a member of the death domain-fold
superfamily (8). This report describes the function of one such PyD containing NBD-LRR
protein, Monarch-1.
A strong clue that CLR proteins are likely to be critical regulators of the immune response,
inflammation, and host response to pathogens is the genetic linkage of several CLR gene
products to susceptibility to autoinflammatory and immunodeficiency disorders. For example,
mutations in MHC2TA are linked to a severe immunodeficiency Bare Lymphocyte Syndrome
(9); mutations in NOD2/CARD15 are associated with a subpopulation of patients with Crohn
disease and Blau syndrome (10–13). Mutations in the CIAS1/Pypaf1/NALP3 gene are
associated with a variety of clinical autoinflammatory syndromes, including familial cold
autoinflammatory syndrome, chronic infantile neurological cutaneous and articular syndrome,
or neonatal-onset multisystem inflammatory disease and Muckle-Wells syndrome (14–18).
Their important role in bacterial infection is underscored by a number of recent studies showing
that the NOD1 protein mediates recognition of a peptidoglycan derived primarily from Gram-
negative bacteria (19, 20), whereas NOD2 mediates the recognition of muramyl dipeptide
(19, 21). These findings support the provocative idea that this family of proteins constitutes
2The abbreviations used are: TLR, Toll-like receptor; NBD, nucleotide binding domain; LRR, leucine-rich repeat; CARD, caspase
activation and recruitment domain; TNF, tumor necrosis factor; TNFR, TNF receptor; TRAF, TNFR-associated factor; IRAK-1, type I
IL-1 receptor-associated protein kinase; Pam3Cys, S-[2,3-bis(palmitoyloxy)-(2-RS)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-Lys-4-OH
trihydrochloride; LPS, lipopolysaccha-ride; PBMC, peripheral blood mononuclear cells; HA, hemagglutinin; HEK cells, human
embryonic kidney cells; IL, interleukin; HRP, horseradish peroxidase; siRNA, small interference RNA; LTR, long terminal repeat;
ELISA, enzyme-linked immunosor-bent assay, ELAM, human E-selectin promoter.
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intracellular sensors of bacterial products and that mutations within these genes lead to a
dysregulated inflammatory response.
In addition to the role of CLR proteins as intracellular cytoplasmic mediators, TLRs in
mammals have rapidly emerged as predominant molecules by which the innate immune system
senses and responds to microbial pathogens (22, 23). There are 13 TLRs that recognize an array
of microbial products derived from bacteria, viruses, and fungi (24–26). TLR signal
transduction is initiated by stimulation followed by the formation of an intracellular signaling
complex with adapter proteins, the predominant one being MyD88 (27). An early step in TLR
signaling is the recruitment of the serine/threonine kinase, IRAK-1, to activated receptor
complexes. IRAK-1 activation is regulated by sequential phosphorylation events (28).
Hyperphosphorylation of IRAK-1 is important for TLR signal transduction as it results in a
decreased affinity for the TLR receptor complex and enables the association of IRAK-1 with
the TRAF6 complex, leading to activation of NFκB and its functional sequelae (29).
We have recently characterized a CLR gene designated as Monarch-1 (30), also known as
Pypaf7 (6). Monarch-1 is expressed primarily by cells of the myeloid lineage, including
monocytes and granulocytes. This study shows that Monarch-1 interferes with IRAK-1
function, resulting in the repression of TLR signaling, and thus, represents a novel negative
regulator of inflammatory responses.
EXPERIMENTAL PROCEDURES
Reagents
The TLR2 agonist, the synthetic lipoprotein S-[2,3-bis-(palmitoyloxy)-(2-RS)-propyl]-N-
palmitoyl-(R)-Cys-(S)-Ser-Lys-4-OH trihydrochloride (Pam3Cys) (ECM) was used at a final
concentration of 100 ng/ml. Initially, lipopolysaccharide (LPS) derived from Escherichia
coli 026:B6 (Sigma-Aldrich) was used at a final concentration of 200 ng/ml; however, for most
of the experiments protein-free, phenol/water-extracted E. coli K235 LPS prepared by the
method of McIntire et al. (31) was used to preclude the contribution of non-TLR4 contaminants
that are often found in commercial LPS preparations (32).
Primary Cell Isolation and Stimulation
Peripheral blood mononu-clear cells (PBMC) were isolated from buffy coats (American Red
Cross) using lymphocyte separation media (ICN, Costa Mesa, CA). For adherent cell
purification, cells were plated at 1 × 108 cells/150 mM plate and allowed to adhere for 2 h at
37 °C. Non-adherent cells were removed by washing three times with phosphate-buffered
saline and replaced with fresh media. Granulocytes were isolated from the red blood cell pellet
after lymphocyte separation media purification after ammonium, chloride, potassium buffer
red blood cell lysis. Granulocytes were plated at 2 × 107 cells/150 mM plate. Cells were
stimulated for 1 h with 200 ng/ml commercial LPS from E. coli (LPS 026:B6; Sigma-Aldrich)
or, where noted, protein free, phenol/water-extracted E. coli LPS K235 prepared as described
in McIntire et al. (31), 1 μg/ml commercial peptidoglycan (Sigma), or 100 ng/ml Pam3Cys
(ECM).
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The complete open reading frame of Monarch-1 was cloned into pcDNA-3 (Invitrogen) as
described (26). Expression plasmids and reporter vectors included HA-MyD88 (33), HA-
IRAK-1, HA-TRAF6 (34), 3×AP-1 luc (35), HA-TRAF2, Myc-RIP1, p65, NFκB luc (36), and
ELAM-luciferase. Monarch-1 truncation mutants were amplified by PCR and cloned into the
pcDNA3.1 V5/HIS vector following the manufacturer’s recommendations (Invitrogen).
Tissue Culture Cells and Conditions
HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium (high glucose)
supplemented with 10% fetal calf serum, 5 mM L-glutamine, and streptomycin-penicillin.
Undifferentiated THP-1 cells were maintained in RPMI 1640 supplemented with 10% fetal
calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and
streptomycin-penicillin. All cells were grown at 37 °C with 5% CO2.
Luciferase Reporter Gene Assays
For transfections 2 × 105 HEK293T cells were plated in 12-well plates followed by transfection
using FuGENE 6 transfection reagent (Roche Applied Science) following the manufacturer’s
recommended protocol. For analysis of TLR receptor signaling molecule induction of NFκB
activity, cells were co-transfected with 250 ng of pNFκB-luc, 100, 250, or 500 ng of pcDNA3-
HA vector, or HA-tagged Monarch-1, and 250 ng of HA-MyD88, FLAG-IRAK-1 HA-TRAF6,
p65, HA-TRAF2, Myc-RIP1 or stimulated with 10 ng/ml TNFα to induce NFκB reporter
activity. For IL-6 gene reporter luciferase assays, 1 × 104 HEK293T cells were plated in 12-
well plates and transfected with 10 ng of IL-6-luc and 10, 20, 50, and 100 ng of pcDNA3-HA
vector or HA-tagged Monarch-1. DNA concentrations were consistent for each transfection.
At 24 h post-transfection, cells were lysed in 1× reporter lysis buffer (Promega), and luciferase
assays were performed per the manufacturer’s instructions.
TLR Reporter Assays
HEK293T cells (2 × 105 cells/well in a 12-well plate) were co-transfected for 3 h with pFLAG-
huTLR4 (7.5 ng/well), pCDNA3-huCD14 (300 ng/well), pEFBOS-HA-huMD-2 (3 ng/well),
or Monarch-1 (0–500 ng/well) together with the NFκB reporter (500 ng/well) and pCMV1-β
gal (100 ng/well). The final DNA quantity was adjusted to 1.5 μg/well, each with the pCDNA-
HA vector using Super-Fect transfection reagent (Qiagen Inc.). Cells were recovered for 20 h,
washed, and stimulated with phenol purified LPS at different concentrations for 5 h. Cells were
lysed and β-galactosidase (Tropix, Galacto-Light system), and luciferase (Promega, luciferase
assay system) activities were analyzed.
Transfection, Immunoprecipitation, and Western Analysis
HEK293T cells were transfected with the indicated plasmid cDNA using FuGENE 6. Cells
were lysed in buffer containing 1% Triton X-100, 150 mM NaCl, 50 mM Tris, pH 8, 50 mM
NaF, 2 mM EDTA, plus a protease inhibitor mixture (Roche Applied Science). Protein
concentrations were determined by Bradford assay (Bio-Rad), and equivalent amounts of
cellular extract were used in subsequent immunoprecipitations. Immunoprecipitates were
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washed four times in lysis buffer and eluted by boiling in Laemmli sample buffer. Samples
were fractionated by SDS-PAGE and transferred to nitrocellulose.
Immunoblots were probed with the indicated primary antibodies and visualized by enhanced
chemiluminescence (Pierce): anti-HA 3F10 (Sigma), mouse monoclonal anti-HA 12CA5 and
anti-HA3F10-HRP (Roche Applied Science), anti-IRAK-1 C-20 and anti-actin-HRP (Santa
Cruz), or anti-FLAG M2-HRP (Sigma). Anti-V-5 was obtained from Invitrogen.
Generation of Antibodies Specific for Human Monarch-1 and Expression Analysis
Polyclonal antisera against human Monarch-1 was generated by immunization of rabbits with
keyhole limpet hemocyanin-conjugated Monarch-1 peptide (RGQREDLVRDTPPGC). The
IgG from the polyclonal antiserum was purified with protein G-Sepharose affinity
chromatography utilizing the manufacturer’s protocols. A mouse monoclonal Monarch-1
antibody was generated from mice immunized with hexahistidine-tagged Monarch-1 (amino
acids 1–593) expressed in E. coli and purified on nickel nitrilotriacetic-agarose (Qia-gen) using
denaturing conditions described in the manufacturer’s protocol. THP-1 cells stimulated with
purified LPS for the indicated time points were lysed in lysis buffer (50 mM Tris-HCl, pH 8.0,
150 mM NaCl, 1% Nonidet P-40) supplemented with Complete protease inhibitor mixture
(Roche Applied Science). Protein concentrations were determined by the Bradford assay (Bio-
Rad), and equivalent amounts of cellular extract were used in subsequent
immunoprecipitations. Immunoprecipitation of Monarch-1 was accomplished utilizing the
rabbit antiMonarch-1 peptide IgG. To control for immunoprecipitation efficiency and
recovery, a rabbit polyclonal antibody for actin (I19, Santa Cruz) was included in the
immunoprecipitation reaction. Monarch-1 and actin immune complexes were precipitated with
protein A-agarose beads. Immunoprecipitates were washed 2 times in lysis buffer and eluted
by boiling in 60 μl of Laemmli sample buffer. Samples were fractionated by SDS-PAGE and
transferred to nitrocellulose. Immunoblots were probed with mouse monoclonal anti-
Monarch-1 and HRP-conjugated anti-actin antibody (C11, Santa Cruz) and visualized by
enhanced chemiluminescence (Pierce).
RNA Preparation and Real-time PCR
Total RNA was isolated according using Trizol reagent (Invitrogen) following the
manufacturer’s protocol. Real-time PCR was performed with the TaqMan sequence detection
system (Applied Biosystems): Monarch-1 forward 5′-AGAG-
GACCTGGTGAGGGATAC-3′, reverse 5′-CTTCCAGAAGGCAT-GTTGAC-3′, probe 5′-
CCCGTCCTCACTTGGGAACCA-3′, IL-6 forward 5′-
GGTACATCCTCGACGGCATCT-3′, reverse 5′-GTGC-CTCTTTGCTGCTTTCAC-3′,
probe 5′-TGTTACTCTTGTTACA-TGTCTCCTTTCTCAGGGCT-3′; 18 S forward 5′-
GCTGCTGGCA-CCAGACTT-3′, reverse 5′-CGGCTACCACATCCAAGG-3′, probe 5′-
CAAATTACCCACTCCCGACCCG-3′. All results are normalized to 18 S ribosomal RNA
internal controls and are expressed in relative numbers.
Monarch-1-specific Small Interference RNA (siRNA) Construction
Wild-type and mutant human Monarch-1 short hairpin RNAs were stably expressed in the
human THP-1 monocyte cell line by infection of the HSPG retrovirus containing short hairpin
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RNA transcription cassettes driven by the H1 RNA promoter and a separate cassette containing
green fluorescent protein driven by the phosphoglycerate kinase promoter. The targeted
sequences are GTCCATGCTGGCACA-CAAG, and the mutant sequence is
GTCCATGCTAACACACAAG (siRNA#1), and GGACATCAACTGTGAGAGG, and the
mutant sequence is GGACATCGGCTGTGAGAGG (siRNA#2).
Promoter-Reporter Retroviral Plasmids
pHermes-κBluc was derived from pHRSpuro-GUS (a gift of H. Blau, Stanford University), a
retroviral vector bearing a self-inactivating 3′ long terminal repeat (LTR) that lacks promoter
and enhancer elements (37). A fragment of pGL3basic (Promega) bearing the transcription
silencer, multicloning site, firefly luciferase-coding sequence was inserted into pHRSpuro-
GUS. This yielded pHermes-luc. pHermes-κBluc was constructed by inserting the 5× NFκB
response element and TATA box from pNFκBluc (Stratagene) into pHermes-luc. Transduction
with pHermes-κBluc retrovirus results in the integration of a synthetic promoter-reporter gene
into the host genome that has no retroviral LTR-driven transcription, because the self-
inactivating 3′ LTR, which lacks promoter and enhancer elements, determines the sequences
of both the 5′ and 3′ LTRs of the integrated retroviral genome. Reporter luciferase retroviral
supernatants were generated as described and used for infection of THP-1 cells. Cells were
stimulated for 6 h with LPS followed by luciferase assay (Promega) as per the manufacturer’s
recommendations.
Retroviral Infections
The A293T cell line were co-transfected with pHSPG-667 (siRNA#1) or pHSPG-1504
(siRNA#2). Monarch-1-specific siRNA vectors or pHermes-κBluc and co-transfected with
pVSV-G (38) and Pgag-pol (38) in 60-mm dishes. Retroviral supernatants (3 ml/well) were
collected 48 and 72 h later, clarified by centrifugation, and used to infect 106 THP-1 cells by
spinning for 3 h at 2500 rpm at 22 °C. Infection was repeated twice on successive days. For
Monarch-1-specific siRNAs, THP-1 cells were purified to greater than 95% green fluorescent
protein-positive using fluorescence-activated cell sorting and used in experiments as pools.
ELISA
THP-1 Monarch-1 siRNA cell populations were stimulated with purified K235 LPS at 200 ng/
ml for 24 h followed by analysis of IL-6 protein expression. The IL-6 cytokine levels in cell
supernatants were analyzed by sandwich ELISA using antibody pairs and protocols
recommended by R&D Systems. The sensitivity of the assays was 16 pg/ml IL-6.
Mycobacterium tuberculosis Infection
THP-1 cells were infected with M. tuberculosis strain H37Rv. M. tuberculosis was grown to
early log phase in Middlebrook 7H9 with oleic acid, albumin, dextrose, catalase media. Colony-
forming units/ml were determined by plating on Middlebrook 7H10 with oleic acid, albumin,
dextrose, catalase media from actively growing cultures A = 2.5 × 108. Bacilli were washed in
0.5% Tween 80, phosphate-buffered saline. Briefly, 2 × 106 THP-1 cells were seeded in 6-
well, flat-bottom cell culture plates 1 day before infection and incubated at 37 °C. Bacteria
were added at a multiplicity of infection of 10 for THP-1 cells. Infection was evaluated by
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measuring colony-forming units. THP-1 cells were collected at the time points indicated; RNA
was made using Trizol reagent (Invitrogen) and evaluated for Monarch-1 or IL-6 expression
by real-time PCR.
Cytokine Bead Array
THP-1 Monarch-1 siRNA#1 cell populations were stimulated with purified E. coli K235 LPS
at 200 ng/ml, with Pam3Cys at 100 ng/ml or with TNFα at 20 ng/ml for 24 h followed by
analysis of cytokine protein expression. The cytokine levels in cell supernatants were analyzed
by Human Inflammation Cytokine Bead Array using antibody pairs and protocols
recommended by R&D Systems.
RESULTS
Expression of Monarch-1 Is Decreased by TLR Signaling in PBMC
Monarch-1 is found primarily in cells of the myeloid and monocytic lineage (6, 30) that
represent a first line of defense against invading microorganisms. These cell types can
discriminate among different pathogens via the capacity of their TLRs to sense pathogen-
associated molecular patterns (39). This causes a very rapid defensive response including the
up-regulation of inflammatory and antimicrobial genes. Because of the highly restricted
expression of Monarch-1 to cells of the innate immune system (30), we hypothesized that
activation of cells via TLRs may influence the expression level of Monarch-1. To test this,
human primary adherent PBMC or granulocytes were isolated and exposed to TLR agonists.
After 1 h of treatment with LPS from E. coli, which activates TLR4, or peptidoglycan, which
activates TLR2, Monarch-1 expression was significantly reduced in both cell types (Fig. 1,
A and B). Because of the concern of contaminants in commercial preparations of TLR agonists,
highly purified LPS was prepared by phenol purification (32). Pam3Cys, the pure synthetic
agonist for TLR2, was used in concert to specifically activate TLR2. Analysis of Monarch-1
expression in granulocytes stimulated with phenol-purified LPS and synthetic Pam3Cys for 1
h confirmed that Monarch-1 expression is down-regulated after TLR activation (Fig. 1C).
Monarch-1 expression is down-regulated upon exposure of PBMC to TNFα(30). To compare
the level of down-regulation to that observed for LPS, human PBMC were stimulated for 1
and 6 h with phenol LPS or TNFα. A similar reduction of Monarch-1 mRNA was observed at
1 h for all treatments (Fig. 1D). At 6 h post-stimulation Monarch-1 expression was further
down-regulated by LPS and TNFα stimulation. This suggests that Monarch-1 is reduced to
similar levels after stimulation of human PBMC with LPS or TNFα.
In the human monocytic cell line, THP-1, Monarch-1 expression was also down-regulated by
exposure to purified LPS for 1 h, and a further reduction was observed at 3 h (Fig. 1E).
Additionally, Monarch-1 protein level, measured by immunoblot analysis with antibodies
raised against recombinant Monarch-1, was decreased in THP-1 cells after exposure to
Pam3Cys over a 6-h time period with respect to untreated cells (Fig. 1F). It was necessary to
immunoprecipitate Monarch-1 protein followed by immunoblotting, as endogenous
Monarch-1 has been difficult to detect in cell lysates. Taken together these data indicate that
Monarch-1 expression is down-regulated after exposure of cells to TLR agonists. This suggests
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that down-regulation of Monarch-1 may be required for the normal defensive response to
microorganisms.
Monarch-1 Down-regulates TLR- and TNF-induced NFκB Activation
The decrease in Monarch-1 expression after TLR and TNFα stimulation suggested that the
down-regulation of Monarch-1 mRNA expression may be necessary for an antimicrobial
response to occur. If this were the case, Monarch-1 would be predicted to exert inhibitory
effects on steady-state cells and to initially dampen potentially overzealous pro-inflammatory
activities that are activated by TLR agonists or by microbial infection. To test this hypothesis,
we co-transfected the HEK293T epithelial cell line with expression vectors for TLR4, MD-2,
and CD14 to reconstitute the TLR4 receptor complex. The ELAM-luciferase reporter, which
can be activated by LPS-induced NFκB translocation, was co-transfected together with varying
amounts of the Monarch-1 expression vector. Cells were treated with LPS, and ELAM-
luciferase reporter activity was measured. Transfection of increasing amounts of Monarch-1
reduced LPS-stimulated ELAM reporter activation in a dose-dependent manner (Fig. 2A). The
inhibitory effect of Monarch-1 was observed at both low and high concentrations of LPS but
may be suboptimal because of the strong signal provided by over-expression of exogenous
TLR4, MD-2, and CD14. To bypass the requirement for overexpression of all three components
to reconstitute an LPS-responsive receptor complex, we examined the effect of Monarch-1 on
the ability of the TLR signaling proteins MyD88, IRAK-1, and TRAF6 as well as the NFκB
subunit p65 to transactivate the NFκB luciferase reporter. This reporter consists of three copies
of the NFκB binding site linked to a luciferase gene. MyD88, IRAK-1, TRAF6, and p65
overexpression caused a dramatic induction of NFκB activation (Fig. 2B). Co-transfection of
a Monarch-1 expression plasmid resulted in decreased NFκB activity induced by MyD88,
IRAK-1, and TRAF6 but not by p65. This indicates Monarch-1 functions upstream of p65. In
the experiments below we show that Monarch-1 interferes with IRAK-1 function. Another
report3 shows that Monarch-1 also interferes with the downstream NFκB-inducing kinase,
which explains the inhibition of TRAF6-activated NFκB by Monarch-1. This is consistent with
the data in Fig. 2A, which measured the affect on an LPS-responsive receptor complex. These
data indicate that the observed capacity of Monarch-1 to diminish TLR signaling is mediated
through its effect on MyD88 and/or IRAK-1 and TRAF6 but not at the level of p65, resulting
in reduced NFκB activity.
To determine whether the negative regulatory effect of Monarch-1 is restricted to the TLR
pathway, we next sought to investigate if Monarch-1 could regulate the TNFR pathway.
HEK293T cells were transfected with different amounts of Monarch-1 expression vector and
either stimulated with TNFα or co-transfected with expression vectors for TNFR signaling
molecules, TRAF2 or RIP1 (Fig. 2C). Overexpression of Monarch-1 resulted in decreased
NFκB activity induced by TNFα, TRAF2, or RIP1. Monarch-1 did not suppress the activation
of an HLA-DR luciferase reporter, suggesting that the effects are specific. These data suggest
that Monarch-1 down-regulates both TLR and TNFR pathways.
3J. Lich, submitted for publication.
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Monarch-1 Associates with IRAK-1 and Down-regulates IRAK-1 Activation
One mechanism by which Monarch-1 could reduce TLR signaling protein-induced NFκB
activity may be through its association with the signaling complex. It is currently believed that
once MyD88 is recruited to the TLR4 complex, and it in turn recruits IRAK-4 to a region
between the MyD88 TIR and death domain and IRAK-1 to its death domain (40). IRAK-4 is
believed to phosphorylate IRAK-1, leading to autophosphorylation and hyperphosphorylation
of IRAK-1 (41). To investigate the mechanism of reduced TLR signaling by Monarch-1,
HEK293T cells were co-transfected with expression vectors for Monarch-1 and the TLR
signaling proteins MyD88 or IRAK-1 followed by immunoprecipitation. Immunoprecipitation
of FLAG-tagged IRAK-1 was performed by using anti-FLAG antibody followed by
immunoblotting for HA-tagged Monarch-1 using an anti-HA antibody. Monarch-1 was found
to co-precipitate with IRAK-1, indicating that these proteins interact in situ (Fig. 3A). In
contrast, no association was detected between Monarch-1 and MyD88 in experiments in which
HA-tagged MyD88 was immunoprecipitated using anti-HA antibody, and immunoblots were
probed with anti-FLAG antibody to detect FLAG-tagged Monarch-1 (Fig. 3B). Upon IRAK-1
overexpression, both native and phosphorylated forms of IRAK-1 could be visualized by
Western analysis, providing a convenient surrogate for IRAK-1 activation in the absence of
extracellular stimuli (Fig. 3C, lane 3) (28). Because IRAK-1 activation is regulated by
sequential phosphorylation events (28), it is possible to distinguish between the species that is
first phosphorylated by IRAK4 (resulting in the appearance of a single band that migrates more
slowly than native IRAK-1 during SDS-PAGE) (40, 41) and the hyperphosphorylated species
that is the consequence of autophosphorylation (28). The appearance of hyperphosphorylated
IRAK-1 was nearly eliminated by the presence of Monarch-1, suggesting inhibition of IRAK-1
autophosphorylation (Fig. 3C, lane 2, band III). In contrast, the faster migrating protein bands
(Fig. 3C, bands I and II, respectively) corresponding to both native and IRAK4-phosphorylated
IRAK-1 were not affected, demonstrating specificity for the inhibition of
hyperphosphorylation.
Presence of the NBD Domain Is Associated with Reduced IRAK-1 Activation
Common to all CLR proteins, Monarch-1 consists of three distinct domains. To determine the
domain(s) responsible for IRAK-1 association, truncation mutants were constructed that
consisted of the N-terminal pyrin domain and the C-terminal LRR domain alone or in
combination with the NBD. The analysis of NBD alone was not possible because this domain
appeared to be very unstable in the absence of either PyD or LRR (not shown). These truncation
mutants (shown in Fig. 4A) were transfected along with recombinant IRAK-1 into HEK293T
cells. Protein complexes were then immunoprecipitated with anti-IRAK-1-specific antibodies.
These experiments revealed that IRAK-1 association is dependent upon the presence of the
NBD region in the presence of either PyD or LRR. Both PyD-NBD and NBD-LRR interacted
with IRAK-1 (Fig. 4C). Neither the pyrin domain (Fig. 4B) nor the LRR region (Fig. 4C) alone
formed molecular complexes with over-expressed IRAK-1. Incongruent with this, the analysis
of IRAK-1 in cellular lysate demonstrated that the reduction of IRAK-1 hyperphosphorylation
(Form III) was most dramatic in the presence of the NBD-LRR mutant followed by the PyD-
NBD mutants (Fig. 4D).
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Monarch-1 Associates with IRAK-1 and Prevents Its Activation in THP-1 Cells
The previous experiment utilized HEK293T cells. To determine whether Monarch-1 negatively
regulates IRAK-1 activation in a more physiologically relevant system, human monocytic
THP-1 cells that stably expressed HA-tagged Monarch-1 (THP-Mon) were produced (Fig. 5).
Endogenous IRAK-1 containing protein complexes were immunoprecipitated with an
IRAK-1-specific antibody, and Western blots were probed with anti-HA to detect co-
precipitating Monarch-1. Complex formation between IRAK-1 and Monarch-1 was induced
after Pam3Cys treatment (Fig. 5B, top panel, lanes 2–4). In contrast, no Monarch-1 was
detected in IRAK-1 immunoprecipitates derived from resting cells, indicating a dependence
upon TLR signaling (Fig. 5B, top panel, lane 1). Notably, when these Western blots were re-
probed to detect immunoprecipitated IRAK-1, sharply reduced levels of hyperphosphorylated
IRAK-1 were detected in THP-Mon cells as compared with their empty vector controls
(compare the second panel, Fig. 5, A and B). This supports the data derived from transient
transfection experiments in HEK293T cells and confirms a role for Monarch-1 in reducing the
accumulation of hyperphosphorylated IRAK-1 in monocytes. These results demonstrate that
Monarch-1 associates with IRAK-1 upon TLR stimulation and inhibits the accumulation of
hyper-phosphorylated IRAK-1. Together these data provide a mechanism by which Monarch-1
inhibits TLR induced NFκB activation.
Endogenous Monarch-1 Functions as a Negative Regulator in Myeloid Cells
The observation that Monarch-1 expression is rapidly decreased after TLR stimulation and
that Monarch-1 is a negative regulator of inflammatory gene activity suggest that
Monarch-1 may be involved in reducing the inflammatory response to pathogens. Specifically,
it may be necessary for innate immune cells to reduce Monarch-1 expression in response to
pathogens to allow for an increase in inflammatory gene induction. If this hypothesis were
correct, the ablation of Monarch-1 expression in myeloid cells would be predicted to result in
increased TLR-induced activation signals. To investigate this, Monarch-1-specific siRNAs
were generated to reduce endogenous Monarch-1 expression in the THP-1 myeloid cell line.
Because of the difficulty in transfecting human myeloid/monocytic cell lines in general and
THP-1 cells specifically, a retroviral based vector was used to express Monarch-1-specific
siRNAs (Fig. 6A). Two sets of siRNAs specific for distinct regions of the Monarch-1 transcript
(designated as siRNA#1 and siRNA#2) were utilized to control for potential nonspecific affects
of siRNA. As further controls, corresponding mutant siRNA with two mutated nucleotides
(designated as mutMon#1 and mutMon#2) were generated to ensure that the observed effects
of siRNA are specific. Monarch-1 short hairpin RNAs were inserted into the pHSPG retroviral
vector. Transcription of siRNAs were driven by the H1 RNA gene promoter situated
immediately upstream of the insertion site in the 3′ LTR. A phosphoglycerate kinase promoter
that drives transcription of the enhanced green fluorescent protein permitted transduced cells
to be separated by fluorescence-activated cell sorting. Therefore, the THP-1 monocytic cell
line was transduced with the siRNA-containing constructs and their corresponding controls.
Sorted enhanced green fluorescent protein-positive cells were maintained in bulk culture and
used to investigate endogenous Monarch-1 function. Expression of Monarch-1 in the four cell
samples were assessed by real-time PCR (Fig. 6B). Compared with their controls, both
siRNA#1 and siRNA#2 achieved greater than 70% reduction in endogenous Monarch-1
Williams et al. Page 10













expression. To assess the level of NFκB activity in the Monarch-1 siRNA cells, the siRNA
cells and their mutant controls were transduced with a retrovirus that contained the luciferase
reporter driven by the NFκB-responsive promoter element 5× NFκB response element and
TATA box from pNFκBluc (Stratagene). Cells were stimulated with phenol-purified LPS
derived from E. coli K235 for 6 h followed by analysis of NFκB luciferase activity. If
Monarch-1 were a negative regulator of pro-inflammatory signaling, ablation of the negative
regulatory activity of Monarch-1 would result in an increase in NFκB activity. Indeed, reduced
Monarch-1 expression achieved by the siRNA resulted in a >1000-fold increase in NFκB
luciferase reporter activity compared with the control mutant siRNA (Fig. 6C). Basal levels of
NFκB reporter activity were higher in the Monarch-1 siRNA cells than in their mutant control
cells, suggesting that endogenous Monarch-1 functions to suppress NFκB activity in the
absence of stimulation. Monarch-1 siRNA#2 cells stimulated with LPS had increased NFκB
activity, although the levels were less dramatic (data not shown). These data suggest that
endogenous Monarch-1 functions to dampen NFκB activation.
Monarch-1 Is a Negative Regulator of IL-6 Cytokine Expression in Response to TLR Agonists
The experiment shown above supports the previous hypothesis that Monarch-1 functions as a
negative regulator of TLR4-induced NFκB activity as assessed by an NFκB reporter assay. To
further investigate the function of Monarch-1 in mediating the inflammatory response to
pathogens, we tested whether endogenous Monarch-1 could regulate the IL-6 gene induced by
TLR activation. Both siRNA#1 and siRNA#2 THP-1 cells were stimulated with E. coli K235
LPS for 6 h followed by analysis of IL-6 mRNA expression by real-time PCR. Stimulation of
both siRNA#1 and siRNA#2 (Mon-1) THP-1 cells resulted in a 4-fold increase in IL-6 mRNA
expression compared with mutant controls (mutMon-1) (Fig. 7A). To investigate if the
increased IL-6 expression were also observed at the protein level, supernatants from LPS-
stimulated Monarch-1 siRNA#1 and siRNA#2 THP-1 cells were analyzed for IL-6 cytokine
expression by ELISA. Consistent with the mRNA data, both Monarch-1 siRNA-containing
lines exhibited increased IL-6 protein expression compared with their mutant controls (Fig.
7B). These data suggest that endogenous Monarch-1 functions as a negative regulator of IL-6
cytokine expression in response to TLR stimulation.
Monarch-1 Is a Negative Regulator of IL-6 Cytokine Expression in Response to M.
tuberculosis Infection
The above observation was obtained with a pure TLR agonist. To assess if this observation
could be extended to a clinically relevant live human pathogen, cells were infected with M.
tuberculosis. M. tuberculosis, the causative agent of human tuberculosis, is the most prevalent
and deadly bacterial infectious disease worldwide and affects one-third of the world population
(42). Incomplete understanding of the molecular nature of protective immune responses has
hampered the development of more effective vaccines and therapies. M. tuberculosis leads to
the induction of inflammatory cytokines through the activation of TLRs (43). To determine
whether exposure of cells to M. tuberculosis could regulate Monarch-1 expression, THP-1
cells were infected with the virulent H37Rv strain of M. tuberculosis for the indicated time
points (Fig. 8A). Monarch-1 expression was reduced after exposure of cells to live M.
tuberculosis for 2 h, and the expression was nearly abolished after 4 h of exposure. This further
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suggests that down-regulation of Monarch-1 may be required for the normal defensive response
to microorganisms. Because IL-6 is an important response of the innate immune cells to
infection by M. tuberculosis (43), we determined if exposure of Monarch-1 siRNA cells to live
bacilli would also result in increased IL-6 cytokine expression. Monarch-1 siRNA THP-1 cells
were infected with the virulent M. tuberculosis followed by analysis of IL-6 cytokine
expression by real-time PCR (Fig. 8B). The bacilli caused a dramatic enhancement of IL-6
production, but cells containing siRNA#1 or siRNA#2 had much higher expression of IL-6
cytokine compared with both wild-type THP-1 cells and the mutant control siRNA.
Monarch-1 Is a Negative Regulator of TLR2-, TLR4- and TNFR-mediated Cytokine Secretion
To investigate more broadly the function of Monarch-1 in mediating the inflammatory response
to TLR agonists as well as TNFα, we investigated whether endogenous Monarch-1 could
regulate pro-inflammatory genes in addition to IL-6. We also investigated if Monarch-1 could
mediate inflammatory responses by other TLR agonists. Taking into consideration that
Monarch-1 inhibits IRAK-1 function, a downstream signaling protein common to both the
TLR2 and TLR4 pathway, we stimulated THP-1 Monarch-1 siRNA cells with E. coli K235
LPS (TLR4) and with the synthetic TLR2 agonist, Pam3Cys, in three separate experiments.
To investigate the role of endogenous Monarch-1 in regulating the TNFR pathway, we also
stimulated these cells with TNFα. Stimulation by Pam3Cys in general resulted in higher
cytokine levels than that observed after LPS stimulation. Supernatant from stimulated cells
was analyzed using the Human Inflammation Cytokine Bead Array (Bio-Rad). In
Monarch-1 siRNA cells we observed increased levels of IL-6, IL-1β, TNFα and a slight
increase in IL-8 when compared with mutMon-1 control cells (Fig. 9A) upon stimulation with
Pam3Cys. Among LPS-treated Monarch-1 siRNA containing cells, an increase in IL-6 and
IL-1β was observed. TNFα and IL-8 were expressed at similar levels in Monarch-1 siRNA
cells compared with the mutant control (Fig. 9B). However, TNFα production in LPS-treated
THP-1 cells was low, and the data should not be over-interpreted. Finally, in response to
TNFα, Monarch-1 siRNA cells produced higher levels of IL-1β with a modest increase in IL-8
compared with control cells (Fig. 9C). These data support the observation that Monarch-1
broadly down-regulates TLR signaling by a TLR2 agonist. It also caused a more specific down-
regulation of IL-6 and IL-1β by a TLR4 agonist. These findings also support the observation
that Monarch-1 is a negative regulator of the TNFR receptor pathway. In a separate set of
experiments using microarray analysis we determined that other genes were not affected by
Monarch-1 including lymphotoxin α, lymphotoxin β, TGFβ1, CCL1 (data not shown). Taken
together, these date imply that Monarch-1 is a broad inhibitor of both TLR and TNFR signal
transduction pathways
DISCUSSION
The inflammatory response to infection represents a two-edged sword, whereas a proper pro-
inflammatory response is necessary to contain infectious microorganisms and foreign antigens,
an overzealous response is detrimental to the host (44). The impact of the latter is clearly
demonstrated by the 660,000 cases of sepsis per year with a 20% mortality rate (45). Although
an array of positive regulators of inflammation has been discovered, relatively few negative
feedback modulators have been identified. The SOCS (suppressor of cytokine signaling)
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molecules represent a major class of negative regulators that are generally induced by
stimulants, including TLR agonists (44). Like SOCS, IRAK-M is also induced by TLR
agonists. Studies using the inactive kinase IRAK-M-deficient mice reveal that IRAK-M is a
negative regulator of TLR signaling and acts by inhibiting the dissociation of IRAK-1/IRAK-4
from the TLR4/MyD88 complex, resulting in blocking of downstream NFκB activation (46).
An alternatively spliced form of MyD88, called MyD88s, binds to TLRs but cannot interact
with IRAK-4. As a result, phosphorylation of IRAK-1 does not occur, and NFκB activation is
abrogated (40, 47). The cytokine-inducible zinc finger protein called A20 and A20-like proteins
including ZNF216 and the zinc finger protein TIZ have been found to inhibit IL-1/TLR4-
mediated activation of NFκB (48). Recently, several CLR proteins are shown to negatively
affect cell activation pathways (49–51). In this report we show that Monarch-1 is also a negative
regulator of pro-inflammatory responses. However, it is the first to exhibit an inhibitory effect
on the TLR signaling pathway induced by MyD88/IRAK-1/TRAF6 and specifically on
IRAK-1 activation.
The conclusion that Monarch-1 is a CLR protein with an anti-inflammatory function is most
convincingly demonstrated by the use of siRNA in myeloid/monocytic cells. Monarch-1 is a
negative regulator of both the TLR and TNFR pathways. Because Monarch-1 is the first CLR
protein that interferes with both TLR2 and TLR4 activation, we explored the molecular
mechanism by which Monarch-1 interferes with this activation. We show that Monarch-1
blocks TLR signaling by association with IRAK-1 and inhibition of IRAK-1
hyperphosphorylation. IRAK-1 activation is regulated by sequential phosphorylation events
involving the initial phosphorylation by IRAK4 and subsequent hyperphosphorylation by
IRAK-1 itself. The hyperphosphorylation of IRAK-1 is important for TLR signal transduction
because it serves to decrease affinity for the TLR receptor complex, which is required for
TRAF6 binding and subsequent downstream signal transduction (28). Our results show that
Monarch-1 clearly interferes with the hyperphosphorylation of IRAK-1. Consistent with these
findings, mitigated IRAK-1 hyperphosphorylation has been observed in endotoxin-tolerant
cells, where LPS exposure no longer stimulates NFκB activation (52, 53). This is thought to
be secondary to a failure to recruit MyD88 to the TLR4 receptor complex (53) and the
subsequent failure to recruit IRAK-1 appropriately to MyD88 (52). In addition, an inhibitory
splice variant of MyD88 has been shown to block phosphorylation of IRAK-1, leading to the
inhibition of LPS-induced NFκB activation (40). Thus, phosphorylation of IRAK-1 is
emerging as a critical regulatory step in the control of TLR signaling and Monarch-1 is an
inhibitor of this important pathway.
An emerging theme among a subgroup of CLRs is that they exhibit negative regulatory
function. Among these, CLR16.2 is unique in its down-regulation of T cell receptor-mediated
cellular activation of NFκB, AP-1, and NFAT (49). PAN1 down-regulates NFκB and the
expression of NFκB regulated genes in a monocytic cell line (50). PYPAF3 down-regulates
LPS-stimulated IL-1β production (51). Both the PAN1 study and the present work relied on
the reduction of endogenous CLR by siRNA. Thus, these two reports provide powerful
evidence that a subgroup of CLRs represents negative regulators of immune and inflammatory
activation.
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In conclusion, this work supports the hypothesis that Monarch-1 normally functions as a
negative regulator of inflammatory activity in resting monocytic/myeloid cells, but its
expression is down-regulated by TLR agonists, TNFα, or whole pathogens. This down-
regulation is necessary for proper inflammatory and anti-microbial responses to proceed. The
down-regulation of Monarch-1 expression is not specific to M. tuberculosis as we have also
observed a decrease of Monarch-1 expression in cells infected with other pathogens (data not
shown). Monarch-1 down-regulates LPS-induced NFκB reporter activity in cells co-
transfected with TLR4 and in cells co-transfected with the TLR/IL-1 receptor signaling
mediators MyD88, IRAK-1, and TRAF6. This inhibition is not specific to the TLR pathway
as Monarch-1 also inhibits TNFR signaling mediators such as TRAF2 and RIP1. Monarch-1
is likely to inhibit multiple pathways, although a focus on the TLR pathway in this report shows
that it interferes with IRAK-1 hyperphosphorylation. Inhibition of Monarch-1 by siRNA in
cell types that naturally express it significantly altered NFκB activation and proinflammatory
cytokine synthesis in response to TLR agonists, TNFα, and virulent M. tuberculosis. A greater
understanding of the ability of Monarch-1 to modulate the immune response to pathogens
including M. tuberculosis will enhance the development of more effective vaccines and
therapies. Taken together these data provide compelling evidence that Monarch-1 is a novel
negative regulator of TLR- and pathogen-mediated pro-inflammatory gene induction through
its interaction with IRAK-1 and its inhibition of IRAK-1 hyperphosphorylation
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FIGURE 1. TLR activation reduces Monarch-1 expression
A, Monarch-1 expression in human adherent peripheral blood cells stimulated for 1 h with
commercial LPS (TLR4 agonist) or commercial peptidoglycan (PGN) (TLR2 agonist). Seven
separate cell preparations were used. B, Monarch-1 expression in human peripheral blood
granulocytes stimulated with commercial LPS (TLR4 agonist) or commercial peptidoglycan
(TLR2 agonist). Three separate cell preparations were used. C, Monarch-1 expression in
human peripheral blood granulocytes stimulated with purified phenol LPS (TLR4 agonist) or
synthetic Pam3Cys (TLR2 agonist). Two separate cell preparations were used. D,
Monarch-1 expression in human adherent peripheral blood cells stimulated with purified
phenol LPS (TLR4 agonist) or TNFα for 1 h (black bars) and 6 h (white bars). Data are
representative of two separate experiments. E, Monarch-1 expression in the human THP-1
monocyte cell line stimulated with phenol-purified LPS for the indicated time points. Data are
the average of three separate experiments. Monarch-1 expression was normalized to the
expression of 18 S rRNA and are represented as -fold difference compared with control. Error
bars represent the S.E. of separate experiments. F, Monarch-1 protein expression in the human
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THP-1 monocyte cell line stimulated with Pam3Cys for the indicated time points. Lysates were
immuno-precipitated (IP) with rabbit anti-Monarch-1 and rat anti-actin followed by
immunoblotting (IB) with either mouse anti-Monarch-1 or goat anti-actin-HRP antibodies.
Data are representative of two separate experiments.
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FIGURE 2. Monarch-1 blocks signaling molecules in the TLR and TNFR pathways
A, HEK293T cells were co-transected with TLR4, CD14, MD-2, different amounts of
Monarch-1, and an ELAM-luciferase reporter construct. After 24 h cells were stimulated with
the indicated concentration of purified E. coli K235 LPS for 5 h. Results represent the mean
± S.E. of three separate experiments. B, HEK293T cells were co-transfected with either vector
alone or expression plasmids for MyD88, IRAK-1, TRAF6, or P65 with/without three
concentrations of Monarch-1, and an NFκB luciferase reporter construct. The results represent
the mean ± S.E. of three separate experiments. C, HEK293T cells were co-transfected with
either vector alone or expression plasmids for TRAF2 or RIP1 or stimulated for 8 h with
TNFαwith/without three concentrations of Monarch-1 and an NFκB luciferase reporter
construct. As a control, cells were co-transfected with an expression plasmid for class II
transactivator (CIITA) and an HLA-DR luciferase reporter construct plus either vector alone
or the highest concentration of Monarch-1 plasmid. The results are representative of four
separate experiments.
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FIGURE 3. Monarch-1 associates with IRAK-1 and limits the accumulation of
hyperphosphorylated forms of the kinase
A, HEK293T cells were transfected with the indicated plasmid DNA. Twenty-four hours later
whole cell lysates (WCL) were prepared, and FLAG-IRAK-1-containing protein complexes
were immunoprecipitated (IP) with anti-FLAG (Fg) M2-agarose beads and separated by SDS-
PAGE. Western blots (IB) were probed with anti-HA (Ha) antibody to detect co-precipitating
HA-Monarch-1. p-, phosphorylated. B, cells were transfected with empty vector or expression
vectors for FLAG-tagged Monarch-1 and HA-MyD88. MyD88-containing protein complexes
were immunoprecipitated with an anti-HA antibody and separated by SDS-PAGE. Western
blots were probed with anti-FLAG to detect co-precipitating FLAG-Monarch-1. C, cells were
transfected with the indicated plasmid DNA, and 24 h later whole cell lysates were prepared
and separated by SDS-PAGE. Western blots were probed with the indicated antibodies. The
hyperphosphorylated form of IRAK-1 (marked as III) was greatly reduced by the presence of
Monarch-1.
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FIGURE 4. The Monarch-1 NBD is required for the association and regulation of IRAK-1
hyperphosphorylation
A, diagram depicting V5-tagged Monarch-1 truncation mutants. B, cells were transfected with
expression vectors encoding the V5-tagged PyD of Monarch-1 and HA-IRAK-1. IRAK-1-
containing protein complexes were immunoprecipitated (IP) with an anti-IRAK-1 antibody
and separated by SDS-PAGE. Western blots (IB) were probed with anti-V5 to detect co-
precipitating V5-PyD. C, cells were transfected with expression vectors encoding the indicated
V5-tagged truncation mutant of Monarch-1 in addition to HA-IRAK-1. IRAK-1-containing
protein complexes were immunoprecipitated with an anti-IRAK-1 antibody and separated by
SDS-PAGE. Western blots were probed with anti-V5 to detect co-precipitating V5-tagged
Monarch-1 truncation mutants. D, whole cell lysates derived from experiments described in
A and B were separated by SDS-PAGE and probed with an anti-IRAK-1 antibody. The
hyperphosphorylated form of IRAK-1 (marked as III) was greatly reduced in the presence of
the NBD-LRR-containing truncation mutant of Monarch-1.
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FIGURE 5. Monarch-1 associates with endogenous IRAK-1 in THP-1 monocytic cells upon TLR
stimulation and limits the accumulation of hyperphosphorylated, endogenous IRAK-1
THP-1 cells stably expressing (A) empty vector (THP-HA-EV) or (B) HA-tagged Monarch-1
(THP-HA-Mon) were stimulated with the TLR2 agonist Pam3Cys4 for the indicated times.
Endogenous IRAK-1-containing protein complexes were immunoprecipitated (IP) with an
anti-IRAK-1 antibody and then fractionated by SDS-PAGE. Western blots were probed with
anti-HA to detect co-precipitating HA-Monarch-1 (top panels). These immunoblots (IB) were
then stripped and probed with anti-IRAK-1 antibodies (second panels). The
hyperphosphorylated form of IRAK-1 was greatly reduced by the presence of Monarch-1.
Interestingly, analysis of cellular lysates indicated that the disappearance of the 80-kDa
nonphosphorylated form of IRAK-1 occurs more slowly in the presence of Monarch-1. Actin
immunoblots were performed to ensure equivalent levels of protein were used among the
samples. p-, phosphorylated.
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FIGURE 6. Monarch-1 is a negative regulator of NFκB activity in the THP-1 monocytic cell line
A, plasmid map of Monarch-1 siRNA in the pHSPG retroviral vector. SiRNAs specific for
Monarch-1 were developed to block Monarch-1 expression followed by analysis of gene
activity. Monarch-1 siRNAs, driven by the H1 RNA promoter, were inserted into the pHSPG
retroviral vector within the 3′ LTR. The presence of a phosphoglycerate kinase (PGK) promoter
driving enhanced green fluorescent protein (eGFP) allows for selection of transduced cells by
fluorescence-activated cell sorting. Two separate Monarch-1 siRNAs and their corresponding
mutant, controls were placed in pHSPG vectors. B, analysis of Monarch-1 expression in
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Monarch-1 (Mon-1) and control mutant (mutMon-1) siRNA bulk monocyte THP-1 cultures as
determined by real-time PCR. THP-1 cells were infected with two different Monarch-1-
specific siRNAs, siRNA#1 and siRNA#2, respectively. Expression was normalized to the
expression of 18 S mRNA and are represented as -fold over mutant control. The results
represent the mean ± S.E. of five separate experiments. C, analysis of NFκB activity in
Monarch-1-specific siRNA cultures. Monarch-1 (Mon-1) and control mutant (mutMon-1)
siRNA cultures were infected with a retroviral based NFκB luciferase reporter. Cultures were
then stimulated with E. coli K235 LPS followed by analysis of NFκB luciferase activity.
Expression is represented as -fold over mutant control. Results represent the mean ± S.E. of
three separate experiments.
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FIGURE 7. Monarch-1 is a negative regulator of IL-6 in monocytic THP-1 cells induced by LPS
Analysis of IL-6 mRNA and protein expression in Monarch-1-specific siRNA cultures. A, two
different Monarch-1 (Mon-1) and control mutant (mut-Mon-1) siRNA cultures, siRNA#1 and
siRNA#2, were stimulated with E. coli K235 LPS followed by analysis of IL-6 transcript
expression by real-time PCR. IL-6 expression was normalized to 18 S RNA and are represented
as exponential numbers. Data are a representative of five separate experiments. B, two different
Monarch-1 (Mon-1) and control mutant (mutMon-1) siRNA cultures, siRNA#1 and siRNA#2,
were stimulated with E. coli K235 LPS followed by analysis of IL-6 cytokine expression by
ELISA. Data are representative of three separate experiments. ND, not determined.
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FIGURE 8. Monarch-1 is a negative regulator of IL-6 in the THP-1 monocytic cell line infected
with virulent M. tuberculosis
A, Monarch-1 transcript expression in the human THP-1 monocytic cell line infected with
virulent M. tuberculosis (Mtb) for the indicated time points. Data represent the average of three
separate experiments measured by real-time PCR. B, analysis of IL-6 mRNA expression in
Monarch-1-specific siRNA cultures. THP-1 cells were compared with Monarch-1 (Mon-1)
and control mutant (mut-Mon-1) siRNA cultures after infection with M. tuberculosis followed
by analysis of IL-6 expression by real-time PCR. Expression was normalized to 18 S RNA,
and data are shown as -fold over unstimulated control. Data are representative of three separate
experiments.
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FIGURE 9. Monarch-1 is a negative regulator of cytokine induction by TLR4 and TLR2 agonists
as well as the TNFR pathway
Monarch-1 (Mon-1) and control mutant (mutMon-1) siRNA cultures were stimulated for 24 h
with Pam3Cys (TLR2 agonist) (A), E. coli K235 LPS (TLR4 agonist) (B), or TNFα (C)
followed by analysis of cytokine expression by cytokine bead assay. Results represent the mean
± S.E. of three separate experiments.
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